These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC AND Treatment
10 results:

  • 1. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
    Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
    Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. NTRK fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
    Principe DR
    Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric cancer with NTRK Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Trk receptor tyrosine kinases in metastasis and cancer therapy.
    Regua AT; Doheny D; Arrigo A; Lo HW
    Discov Med; 2019 Oct; 28(154):195-203. PubMed ID: 31928627
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A novel microRNA located in the
    Dokanehiifard S; Yasari A; Najafi H; Jafarzadeh M; Nikkhah M; Mowla SJ; Soltani BM
    J Biol Chem; 2017 May; 292(18):7566-7577. PubMed ID: 28100780
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
    Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.